With the recent acquisition of Morpeth custom manufcturing site (previously a part of Pfizer Inc.), NPIL Pharma has emerged as one of the leading custom manufacturing organizations across the world.

The Morpeth site is an integrated API & Formulations site with scale up and commercial manufacturing capabilities. The site manufactures a number of finished APIs and has unique technologies in formulations. The Morpeth site routinely supplies over 300 finished dosage forms SKUs (stock keeping units) to over 100 markets including US, Europe and Japan.

For a presentation on the capabilities of the Morpeth site - please click on the following link

Morpeth Site.ppt

With assets across North America, UK and India, NPIL Pharma offers development and commercial scale manufacture services in both API and Formulations.

The early phase business is known as PDS (Pharma Development and Scale-up) while the late-phase offerings are grouped under PMS (Pharma Manufacturing Services). Niche generics, intermediates and vitamins business are organized as Manufactured Molecules/ Building Blocks (MM/BB).

Within the PDS segment, PDS API business is led by Torcan in North America and has a number of kilo labs and pilot plants across US, Europe and India. PDS Formulations activities are carried out at deveopment labs and pilot plants in Mumbai and UK.

Within the PMS segment, PMS API business is supported by technology capabilities in chiral synthesis, biotransformations and in handling High Potency Substances out of UK and India. PMS Formulations services are available from our sites in UK and India.